Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Lü, Shun; Zhang, Wei; Wu, Lin; Wang, Wenxiang; Zhang, Peng; Investigators, Neotorch; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Yang, Lin; Mei, Jiandong; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Yang, Nong; Chen, Yuping; Shan, Jinlu; Xing, Ligang; Tian, Hui; Zhang, Xun; Zhou, Ming; Fang, Haohui; Wu, Guowu; Liu, Yunpeng; Ye, Minhua; Cao, Lejie; Jiang, Jie; Li, Xingya; Zhu, Liangming; Li, Shanqing; Kang, Mingqiang; Zhong, Aihong; Chen, Ke‐Neng; Wu, Nan; Sun, Qian; Ma, Haitao; Cai, Kaican; Wang, Changli; Lin, Gen; Zhu, Kunshou; Zhang, Yu; Zhang, Xiaochun; Hu, Hong; Zhang, Wengang; Chen, Jun; Yang, Zhixiong; Hang, Xiaosheng; Hu, Jian; Huang, Yunchao; Zhang, Zhiye; Zhang, Lumin; Zhang, Liwei; Liu, Lunxu; Lin, Dongmei; Zhang, Jie; Chen, Gang; Li, Yuan; Zhu, Lei; Wang, Weihua; Yu, Wenbo; Cao, Dezhen; Keegan, Patricia; Yao, Sheng

doi:10.1001/jama.2023.24735

Public

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Published in JAMA • Jan 16, 2024

Authors:

Shun Lü

Wei Zhang

Lin Wu

Abstract

Importance: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective: To determine whether toripalimab in combination...

Subject

Medicine

Internal medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!